Citation Impact
Citing Papers
Depression Screening and Patient Outcomes in Cardiovascular Care
2008
Rationally Designed Integrin β3 Mutants Stabilized in the High Affinity Conformation
2008 StandoutNobel
β-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation
2009 StandoutNobel
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
A Comparison of Hirudin with Heparin in the Prevention of Restenosis after Coronary Angioplasty
1995
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
1995
Mechanisms of Thrombus Formation
2008 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors
2004
Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
1999
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
Unstable angina: Pathogenesis, diagnosis, and treatment
1993
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Prospects for Cardiovascular Research
2001 StandoutNobel
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
1995
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Bivalirudin: a review
2005
Apoptosis in the vasculature: mechanisms and functional importance
2000
Human embryonic stem cell transplantation to repair the infarcted myocardium
2007
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
New Antithrombotic Drugs
2012
Platelet-Active Drugs
1998
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
2006 Standout
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials
1999
The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry
2012
Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization
1997
HEPARIN‐INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis‐dependent Patients with Heparin‐induced Thrombocytopenia
2003
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
1999 Standout
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
2001
Unstable Angina Pectoris
2000
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2008 Standout
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
1999
Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
1994
Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group)
1993
Platelet Activation and Atherothrombosis
2007 Standout
Antiplatelet Drugs
2012
Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina
1995
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
2010
The αvβ3 integrin “vitronectin receptor”
1997
The microenvironment of the tumour–host interface
2001 StandoutNature
The biologic and clinical spectrum of Glanzmann's Thrombasthenia: implications of integrin αIIbβ3 for its pathogenesis
1997
Heparin-Induced Thrombocytopenia
2006 Standout
Review: The Integrin αvβ3: Angiogenesis and Apoptosis
1995
Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes
2008
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
2015
Heparin-induced thrombocytopenia and cardiac surgery
2003 Standout
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
1997
Secondary prevention with folic acid: effects on clinical outcomes
2003
Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania.
1997
Atherosclerosis — An Inflammatory Disease
1999 Standout
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
2009 Standout
Heparin-induced thrombocytopenia and cardiac surgery
2003
Transcoronary Transplantation of Progenitor Cells after Myocardial Infarction
2006 Standout
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia
2002
Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy
1999
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
2001
Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia
2002
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
2001 Standout
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI
2000 Standout
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Argatroban
2009
Elastin is an essential determinant of arterial morphogenesis
1998 StandoutNature
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
1994 Standout
Integrins
2002 Standout
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial
2004 Standout
Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization
2000
Advances in Coronary Angioplasty
1996
Platelet-Active Drugs
2001
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Therapeutic monoclonal antibodies
2000
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Antiplatelet Therapy and Proton Pump Inhibition
2012
Abciximab Facilitates the Rate and Extent of Thrombolysis
1999
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
1999
Toward a New Frontier in Myocardial Reperfusion Therapy
1998
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy
1995
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
1998 Standout
Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
1998
Molecular Therapies for Vascular Diseases
1996 Science
Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention
1995
Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination
2002
Recent Stem Cell Advances: Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell–Based Regeneration
2010 StandoutNobel
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
2006 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Association of the Platelet Pl A Polymorphism of Glycoprotein IIb/IIIa and the Fibrinogen Bβ 448 Polymorphism With Myocardial Infarction and Extent of Coronary Artery Disease
1997
Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
1997 Standout
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
1997
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy
1997
Novel Platelet Inhibitors
2001
The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis.
1997
Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions
2001
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention
1995
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction
1999
Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
1997
Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty
1996
Transient intermittent lymphocyte activation is responsible for the instability of angina.
1992
Identification of Active Tissue Factor in Human Coronary Atheroma
1996
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of R.M. Califf being referenced
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
2008
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators
1997
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
1994
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
2009
Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial
1998
Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up
1998
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
1990
Sertraline treatment of major depression in patients with acute MI or unstable angina
2002
Patient-Specific Predictions of Outcomes in Myocardial Infarction for Real-Time Emergency Use: A Thrombolytic Predictive Instrument
1997
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
1994
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
2000
Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes
1998
Failure to achieve optimal anticoagulation with commonly used heparin regimens; a review of GUSTO II
1998